Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 938 vs EYLEA HD in neovascular age-related macular degeneration
jRCT2031260360Phase 3Not yet recruiting
- Sponsor
- Amgen
- Start
- Aug 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of 9MW0813 and aflibercept in exudative macular degeneration (2 arms), sponsored by Amgen. Primary endpoint: Change from baseline in best-corrected visual acuity (BCVA) at Week 12. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
9MW0813aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2031260360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260360.